Theranexus participates in several leading scientific conferences and business conventions

09/06/2022

Download PDF File(253Ko)

THERANEXUS publishes its 2021 full-year results and announces a shift of its strategic focus to rare neurological diseases

25/04/2022
Download PDF File (276Ko)

Information on the number of shares composing share capital

06/04/2022
Download PDF File (276Ko)

Information on the number of shares composing share capital

23/03/2022
Download PDF File (276Ko)

THERANEXUS unveils its scientific advances on the occasion of World Rare Disease Day 2022

24/02/2022
Download PDF File (544Ko)

Information on the number of shares composing share capital

10/02/2022
Download PDF File (276Ko)

THERANEXUS and BBDF start recruitment for phase I/II trial in Batten disease patients

03/02/2022
Download PDF File (373Ko)

THERANEXUS publishes its cash position as of 31 December 2021

13/01/2022
Download PDF File (355Ko)

Semi-annual liquidity contract summary

06/01/2022
Download PDF File (383Ko)

Information on the number of shares composing share capital

04/01/2022
Download PDF File (383Ko)